These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26654523)

  • 1. Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome.
    Namli Kalem M; Hizli D; Kamalak Z; Kösüs A; Kösüs N; Turhan N; Kafali H
    Gynecol Endocrinol; 2016; 32(4):281-4. PubMed ID: 26654523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome.
    Iwata MC; Porquere L; Sorpreso IC; Baracat EC; Soares Júnior JM
    Rev Assoc Med Bras (1992); 2015; 61(3):215-9. PubMed ID: 26248242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum 25-Hydroxy Vitamin D Levels in Turkish Adolescent Girls with Polycystic Ovary Syndrome and the Correlation with Clinical/Biochemical Parameters.
    Bostanci EI; Ozler S; Yilmaz NK; Yesilyurt H
    J Pediatr Adolesc Gynecol; 2018 Jun; 31(3):270-273. PubMed ID: 28782659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile.
    Creatsas G; Koliopoulos C; Mastorakos G
    Ann N Y Acad Sci; 2000; 900():245-52. PubMed ID: 10818412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R; Gokce AI; Yildizhan B; Cim N
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment.
    Zhao T; Xiao X; Li L; Zhu J; He W; Zhang Q; Wu J; Wu X; Yuan T
    Front Endocrinol (Lausanne); 2024; 15():1354214. PubMed ID: 38948525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome.
    Hahn S; Haselhorst U; Tan S; Quadbeck B; Schmidt M; Roesler S; Kimmig R; Mann K; Janssen OE
    Exp Clin Endocrinol Diabetes; 2006 Nov; 114(10):577-83. PubMed ID: 17177140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome.
    Yildizhan R; Kurdoglu M; Adali E; Kolusari A; Yildizhan B; Sahin HG; Kamaci M
    Arch Gynecol Obstet; 2009 Oct; 280(4):559-63. PubMed ID: 19214546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
    Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
    Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of drospirenone (3 mg) with ethinyl estradiol (30 mcg) containing pills on ovarian blood flows in women with polycystic ovary syndrome: a case controlled study.
    Okyay E; Gode F; Acet F; Bodur T; Cagliyan E; Sahan C; Posaci C; Gulekli B
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():93-9. PubMed ID: 25063905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome.
    Somunkiran A; Yavuz T; Yucel O; Ozdemir I
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):196-201. PubMed ID: 17335955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome.
    Wehr E; Pilz S; Schweighofer N; Giuliani A; Kopera D; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2009 Oct; 161(4):575-82. PubMed ID: 19628650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome.
    Wehr E; Trummer O; Giuliani A; Gruber HJ; Pieber TR; Obermayer-Pietsch B
    Eur J Endocrinol; 2011 May; 164(5):741-9. PubMed ID: 21389086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
    De Diego MV; Gómez-Pardo O; Groar JK; López-Escobar A; Martín-Estal I; Castilla-Cortázar I; Rodríguez-Zambrano MÁ
    Arch Gynecol Obstet; 2020 Nov; 302(5):1169-1179. PubMed ID: 32770354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
    Adeniji AA; Essah PA; Nestler JE; Cheang KI
    J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
    Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
    Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.